Study details
Enrolling now
MAD Study of IA-14069
ILAb Co., Ltd.
NCT IDNCT05533372ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
75
Study length
about 3.4 years
Ages
18–70
Locations
1 site in KS
About this study
This trial is testing a treatment called IA-14069. It's being done in healthy volunteers and people with rheumatoid arthritis (RA). The goal is to see how safe, well-tolerated, and effective the treatment is.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take IA-14069
- 2.Take Methotrexate
- 3.Take Placebo
PhasePhase 1
DrugMethotrexate
Routeoral
Primary goalIncidnece and severity of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
methotrexate
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Incidnece and severity of adverse events
Secondary: AUC, Cmax, Tmax
Body systems
Immune